EMA Proposes Paradigm Shift to Include Pregnant and Breastfeeding Women in Clinical Trials
核心洞察
The European Medicines Agency (搜索) has released new guidance recommending that pregnant and breastfeeding women should be included in clinical trials for all medicines intended for people who can potentially give birth to children.
Currently, less than 0.4% of EU clinical trials include pregnant participants and only 0.1% include lactating individuals, leading to treatment decisions made without essential safety and efficacy data.
The new guideline, developed through the International Council for Harmonisation (搜索), represents a "change in paradigm" and is open for public consultation until September 15th.
The European Medicines Agency (搜索) has introduced groundbreaking guidance that could fundamentally transform how clinical trials are conducted, recommending the inclusion of pregnant and breastfeeding women in drug studies for medicines intended for people who can potentially give birth to children.
The new document, currently open for public consultation until September 15th, represents what the EMA describes as "a change in paradigm" in medicine development. The guidance was developed jointly by global regulators and medicines developers through the International Council for Harmonisation (搜索) of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
Current Exclusion Creates Data Gaps
Data from the EU Clinical Trials Information System (CTIS) reveals the stark underrepresentation of these populations in clinical research. Less than 0.4% of all trials carried out in the EU include pregnant subjects, with this figure dropping to just 0.1% for lactating individuals. This pattern mirrors findings from the United States, where a recent study estimated that less than 1% of clinical drug trials include pregnant participants.
The low participation rates stem from systematic exclusion practices, where pregnant and breastfeeding individuals are often excluded from clinical trials at the outset. Additionally, subjects who become pregnant while participating in a trial are frequently discontinued from further participation.
"As a result, product leaflets usually lack details about the benefits and risks of a medicine, specifically in pregnancy (搜索) and breastfeeding, requiring patients and healthcare professionals to make treatment decisions without this essential information," the EMA stated in introducing the new guidance.
Clinical Impact and Safety Concerns
The absence of pregnancy (搜索)-specific data creates significant clinical challenges, as the EMA notes that "the vast majority of pregnant people take medications, for example, because of chronic diseases (搜索), infections (搜索), or pregnancy complications (搜索)." Similarly, breastfeeding populations face comparable medication needs.
The current data gap "can lead to suboptimal treatment decisions and potential harm," according to the EMA. A recent paper published in The Lancet concluded that the current low rates of inclusion "contributes to fragmented maternal health policies and practice, as well as exacerbating gender, social, and geographical inequalities."
Research indicates that rates of inclusion of pregnant participants in drug trials have remained unchanged over the past 15 years, despite ongoing calls for greater involvement and recognition of the safety and efficacy concerns this under-representation raises for maternal and child health.
Regulatory Framework and Implementation
The new guideline outlines scientific, regulatory, and ethical considerations for designing both pre- and post-marketing trials to include and retain pregnant and breastfeeding individuals. The framework establishes principles and conditions that must be met to ensure the safety of clinical trial participants, as well as their fetuses and babies.
The EMA is encouraging medicine developers to engage in "proactive planning and early consultation" with regulatory authorities "to ensure the safety and efficacy of treatments during pregnancy (搜索) and breastfeeding." This approach aims to generate robust clinical data that will enable these populations and their healthcare providers to make informed, evidence-based treatment decisions.
The guidance addresses the design of clinical trials for both pre- and post-authorization studies, providing a comprehensive framework for including these previously underrepresented populations in pharmaceutical research.